Lorenzo, R.B., Lorenzo, L.S. and González-Martín, A. 2017. Will the carboplatin-paclitaxel-bevacizumab combination become the preferred option as the first line in advanced cervical cancer? A small experience from a single oncologic Center:  . Cancer Breaking News. 5, 1 (Apr. 2017), 21–24. DOI:https://doi.org/10.19156/cbn.2017.0035.